{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Complement+Mediated+Diseases",
    "query": {
      "condition": "Complement Mediated Diseases"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Complement+Mediated+Diseases&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T09:18:39.942Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07046806",
      "title": "Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Angioedema (HAE)",
        "Angioedema",
        "Bradykinin-mediated Angioedema",
        "C1 Inhibitor Deficiency"
      ],
      "interventions": [
        {
          "name": "Deucrictibant XR tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo comparator to XR tablet",
          "type": "DRUG"
        },
        {
          "name": "Deucrictibant 20 mg capsule",
          "type": "DRUG"
        },
        {
          "name": "Placebo comparator to 20 mg capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Institute for Asthma and Allergy",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2025-03-10",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2025-07-02",
      "last_synced_at": "2026-05-22T09:18:39.942Z",
      "location_count": 1,
      "location_summary": "Wheaton, Maryland",
      "locations": [
        {
          "city": "Wheaton",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07046806"
    },
    {
      "nct_id": "NCT06371417",
      "title": "Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Antiphospholipid Syndrome (APS)",
        "Bullous Pemphigoid (BP)",
        "Behçet's Syndrome (BS)",
        "Dermatomyositis (DM)",
        "Immune-mediated Necrotizing Myopathy (IMNM)",
        "Immune Thrombocytopenia (ITP)"
      ],
      "interventions": [
        {
          "name": "RAY121",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chugai Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 144,
      "start_date": "2024-08-19",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-05-22T09:18:39.942Z",
      "location_count": 11,
      "location_summary": "Orange, California • Baltimore, Maryland • Lake Success, New York + 8 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06371417"
    },
    {
      "nct_id": "NCT06989359",
      "title": "Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgAN",
        "C3G",
        "Complement-mediated Kidney Disease",
        "IgA Nephropathy (IgAN)",
        "IC-MPGN"
      ],
      "interventions": [
        {
          "name": "ADX-038 Dose Level 2",
          "type": "DRUG"
        },
        {
          "name": "ADX-038 Dose Level 1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ADARx Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2025-08-28",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-05-22T09:18:39.942Z",
      "location_count": 11,
      "location_summary": "Doral, Florida • Miami, Florida • Pembroke Pines, Florida + 8 more",
      "locations": [
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06989359"
    },
    {
      "nct_id": "NCT06853223",
      "title": "This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Graft Dysfunction",
        "Lung Transplantation",
        "Acute Lung Injury(ALI)",
        "Natural Killer Cell Mediated Immunity"
      ],
      "interventions": [
        {
          "name": "Maraviroc",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2025-12-07",
      "completion_date": "2028-08-14",
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-05-22T09:18:39.942Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06853223"
    },
    {
      "nct_id": "NCT02013037",
      "title": "The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Antibody-mediated Rejection",
        "Hyperacute Rejection of Cardiac Transplant",
        "Left Ventricular Dysfunction",
        "Cardiac Allograft Vasculopathy",
        "Heart Graft Dysfunction"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 36,
      "start_date": "2012-11",
      "completion_date": "2020-04-30",
      "has_results": true,
      "last_update_posted_date": "2021-05-03",
      "last_synced_at": "2026-05-22T09:18:39.942Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02013037"
    },
    {
      "nct_id": "NCT03316521",
      "title": "First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Complement Mediated Diseases"
      ],
      "interventions": [
        {
          "name": "AMY-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amyndas Pharmaceuticals S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "MALE",
        "summary": "18 Years to 60 Years · Male only"
      },
      "enrollment_count": 50,
      "start_date": "2017-04-24",
      "completion_date": "2017-11-30",
      "has_results": false,
      "last_update_posted_date": "2018-01-16",
      "last_synced_at": "2026-05-22T09:18:39.942Z",
      "location_count": 1,
      "location_summary": "High Point, North Carolina",
      "locations": [
        {
          "city": "High Point",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03316521"
    },
    {
      "nct_id": "NCT02983006",
      "title": "Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "DS-8273a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2016-10",
      "completion_date": "2021-01-01",
      "has_results": false,
      "last_update_posted_date": "2021-10-18",
      "last_synced_at": "2026-05-22T09:18:39.942Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02983006"
    },
    {
      "nct_id": "NCT03369236",
      "title": "A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "C3 Glomerulopathy",
        "C3 Glomerulonephritis",
        "Dense Deposit Disease"
      ],
      "interventions": [
        {
          "name": "Danicopan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "17 Years to 65 Years"
      },
      "enrollment_count": 13,
      "start_date": "2018-06-12",
      "completion_date": "2020-12-18",
      "has_results": true,
      "last_update_posted_date": "2022-10-14",
      "last_synced_at": "2026-05-22T09:18:39.942Z",
      "location_count": 6,
      "location_summary": "Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03369236"
    },
    {
      "nct_id": "NCT05121376",
      "title": "A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Angioedema",
        "HAE"
      ],
      "interventions": [
        {
          "name": "Dose 1 of BMN 331",
          "type": "GENETIC"
        },
        {
          "name": "Dose 2 of BMN 331",
          "type": "GENETIC"
        },
        {
          "name": "Dose 3 of BMN 331",
          "type": "GENETIC"
        },
        {
          "name": "Dose 4 of BMN 331",
          "type": "GENETIC"
        },
        {
          "name": "Dose 5 of BMN 331",
          "type": "GENETIC"
        },
        {
          "name": "Dose 6 of BMN 331",
          "type": "GENETIC"
        },
        {
          "name": "Dose 7 of BMN 331",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "BioMarin Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2022-02-15",
      "completion_date": "2028-11",
      "has_results": false,
      "last_update_posted_date": "2024-05-16",
      "last_synced_at": "2026-05-22T09:18:39.942Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05121376"
    },
    {
      "nct_id": "NCT05095623",
      "title": "A Natural History Study to Assess the Clinical Outcomes of Patients With Complement Factor I Deficiency-Mediated Disease",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Recurrent Bacterial Infection, Autoimmune Disorder"
      ],
      "interventions": [
        {
          "name": "Natural History Observation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Catalyst Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 3,
      "start_date": "2021-08-31",
      "completion_date": "2022-02-10",
      "has_results": false,
      "last_update_posted_date": "2022-04-08",
      "last_synced_at": "2026-05-22T09:18:39.942Z",
      "location_count": 1,
      "location_summary": "Huntsville, Alabama",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05095623"
    }
  ]
}